Unable to display view head.php file not found.
 
American Journal of Medicine
 

Eikelboom - Evidence from the Randomized Trials - Figure 19
RE-SONATE: Any Bleeding

There was a substantial increase of about 40% to 50% in bleeding with dabigatran in RE-SONATE, which is what might be expected but is nonetheless an important finding as physicians weigh the balance between risk and benefits of extended treatment. [9] Eikelboom J. Am J Med 2013; published on-line at http://education.amjmed.com/00000. 

References

[9] Schulman S, Kearon C, Kakkar AK, et al; for the RE-MEDY and the RE-SONATE Trials Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709-718.

Unable to display view foot.php file not found.